Rigel Pharmaceuticals, Inc. (RIGL)
39.65
-6.06
(-13.26%)
USD |
NASDAQ |
Nov 06, 16:00
39.60
-0.05
(-0.13%)
After-Hours: 20:00
Rigel Pharmaceuticals Net Income (Quarterly) : 17.29M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.29M |
| March 31, 2026 | 8.654M |
| December 31, 2025 | 268.06M |
| September 30, 2025 | 27.90M |
| June 30, 2025 | 59.61M |
| March 31, 2025 | 11.45M |
| December 31, 2024 | 14.34M |
| September 30, 2024 | 12.42M |
| June 30, 2024 | -1.03M |
| March 31, 2024 | -8.247M |
| December 31, 2023 | 0.737M |
| September 30, 2023 | -5.692M |
| June 30, 2023 | -6.60M |
| March 31, 2023 | -13.54M |
| December 31, 2022 | 1.401M |
| September 30, 2022 | -19.04M |
| June 30, 2022 | -13.49M |
| March 31, 2022 | -27.44M |
| December 31, 2021 | -22.64M |
| September 30, 2021 | -20.95M |
| June 30, 2021 | -13.82M |
| March 31, 2021 | 39.50M |
| December 31, 2020 | -19.24M |
| September 30, 2020 | -14.17M |
| June 30, 2020 | -17.58M |
| Date | Value |
|---|---|
| March 31, 2020 | 21.24M |
| December 31, 2019 | -17.20M |
| September 30, 2019 | -11.49M |
| June 30, 2019 | -20.61M |
| March 31, 2019 | -17.60M |
| December 31, 2018 | 3.228M |
| September 30, 2018 | -23.77M |
| June 30, 2018 | -25.56M |
| March 31, 2018 | -24.38M |
| December 31, 2017 | -25.87M |
| September 30, 2017 | -17.66M |
| June 30, 2017 | -19.15M |
| March 31, 2017 | -15.31M |
| December 31, 2016 | -15.59M |
| September 30, 2016 | -22.63M |
| June 30, 2016 | -13.53M |
| March 31, 2016 | -17.46M |
| December 31, 2015 | -12.69M |
| September 30, 2015 | -6.672M |
| June 30, 2015 | -13.91M |
| March 31, 2015 | -18.19M |
| December 31, 2014 | -22.27M |
| September 30, 2014 | -20.94M |
| June 30, 2014 | -25.39M |
| March 31, 2014 | -22.30M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cytokinetics, Inc. | -190.07M |
| Inovio Pharmaceuticals, Inc. | -6.012M |
| United Therapeutics Corp. | 258.60M |
| Verastem, Inc. | -34.67M |
| Marker Therapeutics, Inc. | -1.826M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 78.70M |
| Total Expenses (Quarterly) | 61.41M |
| EPS Diluted (Quarterly) | 0.8835 |
| Enterprise Value | 684.25M |
| Gross Profit Margin (Quarterly) | 89.17% |
| Profit Margin (Quarterly) | 21.97% |
| Earnings Yield | 41.17% |
| Operating Earnings Yield | 11.23% |
| Normalized Earnings Yield | 41.18 |